1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
Clinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well short of expectations on Wednesday. While one analyst trimmed her price target on the stock in response, she's still extremely bullish on its prospects. In fact, she believes it could nearly triple before long. Might she be on to something here?
That analyst is prognosticator Samantha Semenkow. In the wake of Editas' latest earnings release, she shaved $1 off her price target on the company to $15 per share. She maintained her buy recommendation, since that lower target was still roughly three times the stock's price at the time.
Semenkow is staying the course despite Editas' disappointing first-quarter performance. The gene-editing company's revenue came in at $1.1 million in the first quarter, a precipitous drop from $9.9 million in the same period a year ago and far below the average pundit estimate of slightly less than $11 million.
Source Fool.com
Citigroup Inc. Stock
With 22 Buy predictions and 2 Sell predictions Citigroup Inc. is one of the favorites of our community.
As a result the target price of 71 € shows a positive potential of 25.33% compared to the current price of 56.65 € for Citigroup Inc..